Suppr超能文献

用布雷沙诺龙治疗成年女性产后抑郁症。

Brexanolone to Treat Postpartum Depression in Adult Women.

机构信息

Cornett, PhD, Rando, BS, Labbé, Kaye, MD, PhD, Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA. Perkins, BS, LSU School of Medicine, LSUHSC New Orleans, New Orleans, LA. Kaye, Pharm.D., FASCP, FCPhA, Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA. Viswanath, MD, Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, Valley Anesthesiology and Pain Consultants - Envision Physician Services, Phoenix, AZ, University of Arizona College of Medicine - Phoenix, Department of Anesthesiology, Phoenix, AZ, University School of Medicine, Department of Anesthesiology, Omaha, NE. Urits, MD, Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Boston, MA.

出版信息

Psychopharmacol Bull. 2021 Mar 16;51(2):115-130.

Abstract

ZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Further studies are necessary to make this determination.

摘要

Zulresso(Brexanolone)是一种新型的 FDA 批准的治疗中度至重度产后抑郁症的药物。产后抑郁症可在出现抑郁症状的女性中诊断出来,这些症状可能早在第三个三个月到分娩后 4 周内表现为认知、行为或情绪障碍。Brexanolone 的疗效表明,神经甾体如孕烷醇酮对于治疗 PPD 很重要。然而,目前尚不清楚 Brexanolone 在给药后 30 天或更长时间内是否能持续缓解抑郁症状。还需要进一步的研究来确定这一点。

相似文献

1
Brexanolone to Treat Postpartum Depression in Adult Women.
Psychopharmacol Bull. 2021 Mar 16;51(2):115-130.
2
Brexanolone for the treatment of patients with postpartum depression.
Drugs Today (Barc). 2019 Sep;55(9):537-544. doi: 10.1358/dot.2019.55.9.3040864.
3
Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
Ann Pharmacother. 2020 Feb;54(2):157-163. doi: 10.1177/1060028019873320. Epub 2019 Sep 3.
4
Brexanolone for postpartum depression.
Am J Health Syst Pharm. 2020 Feb 19;77(5):336-345. doi: 10.1093/ajhp/zxz333.
5
Evaluating brexanolone for the treatment of postpartum depression.
Expert Opin Pharmacother. 2021 Jun;22(8):959-964. doi: 10.1080/14656566.2021.1897105. Epub 2021 Mar 12.
6
Brexanolone Is the First Drug Specifically for Postpartum Depression.
Nurs Womens Health. 2019 Oct;23(5):450-454. doi: 10.1016/j.nwh.2019.07.004. Epub 2019 Aug 22.
7
Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
Clin Ther. 2020 Jan;42(1):231-235. doi: 10.1016/j.clinthera.2019.11.005. Epub 2020 Jan 3.
8
Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
Pharmacotherapy. 2019 Nov;39(11):1105-1112. doi: 10.1002/phar.2331. Epub 2019 Oct 7.
9
Brexanolone (Zulresso) for postpartum depression.
Med Lett Drugs Ther. 2019 May 6;61(1571):68-70.
10
Treating postpartum depression with brexanolone.
Nursing. 2020 May;50(5):48-53. doi: 10.1097/01.NURSE.0000657072.85990.5a.

引用本文的文献

1
New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?
Pharmaceuticals (Basel). 2025 Apr 30;18(5):665. doi: 10.3390/ph18050665.
4
Interventional Psychiatry in India: Bridging Treatment Gaps and Expanding Horizons in Mental Health.
Indian J Psychol Med. 2024 Dec 9:02537176241294146. doi: 10.1177/02537176241294146.
5
Navigating the Intersection of Technology and Depression Precision Medicine.
Adv Exp Med Biol. 2024;1456:401-426. doi: 10.1007/978-981-97-4402-2_20.
9
Exploring Ciprofol Alternatives: A Comprehensive Review of Intravenous Anesthesia Options.
Cureus. 2024 Apr 4;16(4):e57581. doi: 10.7759/cureus.57581. eCollection 2024 Apr.
10
C-3 Steroidal Hemiesters as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 10.
ACS Omega. 2024 Feb 28;9(10):12116-12124. doi: 10.1021/acsomega.3c10148. eCollection 2024 Mar 12.

本文引用的文献

1
Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective.
Neurobiol Stress. 2020 Mar 14;12:100215. doi: 10.1016/j.ynstr.2020.100215. eCollection 2020 May.
2
Allopregnanolone in postpartum depression: Role in pathophysiology and treatment.
Neurobiol Stress. 2020 Feb 3;12:100212. doi: 10.1016/j.ynstr.2020.100212. eCollection 2020 May.
3
Realising the therapeutic potential of neuroactive steroid modulators of the GABA receptor.
Neurobiol Stress. 2019 Dec 23;12:100207. doi: 10.1016/j.ynstr.2019.100207. eCollection 2020 May.
4
Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States.
J Manag Care Spec Pharm. 2020 May;26(5):627-638. doi: 10.18553/jmcp.2020.19306. Epub 2020 Mar 19.
5
Use of Brexanolone for Postpartum Depression.
Innov Clin Neurosci. 2019 Nov 1;16(11-12):32-35.
6
Allopregnanolone-based treatments for postpartum depression: Why/how do they work?
Neurobiol Stress. 2019 Oct 24;11:100198. doi: 10.1016/j.ynstr.2019.100198. eCollection 2019 Nov.
7
Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
Ann Pharmacother. 2020 Feb;54(2):157-163. doi: 10.1177/1060028019873320. Epub 2019 Sep 3.
8
Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.
Psychiatry Res. 2019 Sep;279:83-89. doi: 10.1016/j.psychres.2019.07.006. Epub 2019 Jul 4.
10
Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
CNS Drugs. 2019 Mar;33(3):265-282. doi: 10.1007/s40263-019-00605-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验